CABA - CIK 0001759138
Cabaletta Bio, Inc. (CABA) reported net income of -$167.86M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$167.86M | -44.9% |
| FY 2024 | -$115.86M | -71.2% |
| FY 2023 | -$67.68M | -27.8% |
| FY 2022 | -$52.98M | -14.4% |
| FY 2021 | -$46.29M | -38.8% |
| FY 2020 | -$33.34M | -96.8% |
| FY 2019 | -$16.94M | -38.9% |
| FY 2018 | -$12.20M | - |
Cabaletta Bio, Inc. (CABA) reported net income of -$167.86M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, Cabaletta Bio, Inc.'s net income declined from -$12.20M to -$167.86M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.